TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
CVS Pharmacy and several subsidiaries agreed to pay $315 million to resolve a 2024 Justice Department lawsuit alleging they filled medically unnecessary opioid prescriptions. CVS disputes the allegations, and the settlement does not admit wrongdoing; it also requires additional safeguards for dispensing controlled substances.
CVS Pharmacy and several subsidiaries have agreed to pay $315 million to settle a Justice Department lawsuit alleging the company unlawfully dispensed medically unnecessary opioid prescriptions. The agreement also requires additional safeguards for opioid and other controlled-substance dispensing; CVS says it strongly disagrees with the allegations and that the settlement admits no wrongdoing.
The Justice Department announced the settlement Tuesday, resolving a lawsuit filed in 2024. The case alleged CVS violated the Controlled Substances Act by filling illegitimate prescriptions, including high-dose prescriptions for potent opioids. Prosecutors said some prescriptions came from providers they described as “pill mills”—prescribers allegedly issuing drugs without a legitimate medical purpose.
The lawsuit also alleged that CVS’s staffing levels, performance metrics and incentive compensation policies contributed to pharmacists filling prescriptions without adequately confirming they were legitimate. It said many of the prescriptions were billed to and reimbursed by Medicaid and other federal health programs. These points are allegations in the government’s case, not findings established by the settlement.
Alongside the payment, CVS must implement additional safeguards so prescriptions for opioids and other controlled substances are dispensed only when medically appropriate, according to the Justice Department. The source report does not provide a schedule for the payments or give further detail on how the new safeguards will be monitored.
Financial Penalty and Pharmacy Safeguards
The settlement combines a substantial payment with changes to how a major pharmacy chain handles controlled-substance prescriptions. The safeguards address the core conduct alleged by the government: that prescriptions lacking a legitimate medical purpose were filled despite warning signs. Their practical effect will depend on how CVS applies them and how compliance is assessed, details not provided in the announcement.
The case also puts pharmacy practices under federal scrutiny as part of wider efforts to address the opioid and overdose crisis. The Justice Department framed the deal as enforcement against pharmacies, while CVS maintained that its pharmacists were trained in medication safety and that it had programs to support their decisions. The agreement resolves this case, but does not establish that CVS admitted the government’s allegations.
The financial consequences extend beyond the company. The source report says prescriptions at issue were often reimbursed by federal healthcare programs, while the settlement adds safeguards to dispensing. It does not specify how the $315 million will be distributed or whether any portion is earmarked for opioid prevention, treatment or other public-health programs.
As an affiliate, we earn on qualifying purchases.
The 2024 Case and Wider Settlements
The Justice Department lawsuit was filed in 2024 under President Joe Biden’s administration. It alleged CVS filled large quantities of opioid prescriptions from providers the government considered suspicious, and linked those practices to dependence and addiction. CVS said at the time that pharmacists faced “vague, undefined, and ever-changing standards” for deciding whether opioid prescriptions should be filled.
The settlement comes amid a longer series of opioid-related agreements involving drug manufacturers, distributors, pharmacies and other companies. According to the source report, U.S. governments have secured settlements totaling more than $50 billion over the past decade. Most of that money and most of the agreements have involved state and local governments; the federal government has also reached deals with pharmacy chains, including Walgreens and Walmart in the past two years.
The report says the opioid crisis has been linked to more than 100,000 U.S. deaths in some years, while overdose deaths have fallen sharply more recently. That broader public-health history is relevant to the enforcement effort, but the settlement announcement does not establish that CVS’s conduct caused a specific number of deaths or measure the deal’s effect on overdose rates.
““Today’s settlement is a significant milestone in the Justice Department’s efforts to combat the opioid epidemic by cracking down on pharmacies who unlawfully fulfill prescriptions for controlled substances.””
— Associate Attorney General Stanley Woodward
As an affiliate, we earn on qualifying purchases.
Terms Still Awaiting Detail
The settlement resolves the lawsuit, but the information provided does not say whether a court has entered a final approval order or outline the full implementation timetable. It also does not explain how the $315 million will be paid, who will receive the money, or what penalties could follow if CVS fails to meet the new requirements.
The government’s account of CVS’s prescribing practices remains an allegation that the company disputes. The settlement does not include an admission of wrongdoing, and the announcement does not report findings on the specific prescriptions, pharmacists or locations involved. It is also unclear how regulators will measure whether the additional safeguards prevent inappropriate dispensing.
controlled substance prescription monitoring device
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Implementation and Oversight Ahead
CVS is required under the settlement to put additional dispensing safeguards in place. The Justice Department described the requirement but did not provide a public timeline, specific operational steps or details about oversight in the source material. Those terms will determine how the agreement changes pharmacy procedures in practice.
Further information may clarify payment arrangements, compliance checks and the duration of the obligations. Until those details are available, the confirmed terms are the $315 million settlement and CVS’s commitment to additional safeguards, alongside the company’s continuing denial of the allegations.
As an affiliate, we earn on qualifying purchases.
Key Questions
How much will CVS pay?
CVS Pharmacy and several subsidiaries agreed to pay $315 million to resolve the Justice Department case. The report does not specify the payment schedule or how the money will be distributed.
What did the Justice Department allege?
The department alleged CVS unlawfully filled medically unnecessary opioid prescriptions, including prescriptions it said came from providers issuing drugs without a legitimate medical purpose. It also alleged that staffing levels and company performance policies contributed to inadequate checks. CVS disputes the claims.
Did CVS admit wrongdoing?
No. CVS said it strongly disagreed with the lawsuit’s claims and that the settlement admits no wrongdoing.
What changes does the settlement require?
CVS must implement additional safeguards so prescriptions for opioids and other controlled substances are dispensed only when medically appropriate. The announcement does not give a detailed implementation plan or oversight schedule.
When was the lawsuit filed?
The Justice Department filed the lawsuit in 2024. The settlement was announced on October 13, 2026.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
